Combinations of monoclonal antibodies can distinguish primary lung tumors from metastatic lung tumors sampled by fine needle aspiration biopsy

Mottolese, Marcella; Venturo, Irene; Rinaldi, Massimo; Campioni, N; Aluffi, A.; Curcio, C. Gallo; Donnorso, R. Perrone; Natali, Pier Giorgio

doi:10.1002/1097-0142(19891215)64:12<2493::aid-cncr2820641215>3.0.co;2-s

Cited by 8 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, a significant number of cases cannot be diagnosed beyond the general term of 'adenocarcinoma' and 'carcinoma' until the histological examination becomes available (Giardini et al, 1993;Van der Gaast et al, 1996). Because previous studies of ours have shown that the combined evaluation of a large and well-characterized panel of MAbs on cytological specimens has the capability of detecting tumour origin in patients with cryptic tumours (Mottolese et al, 1988(Mottolese et al, , 1989(Mottolese et al, , 1990(Mottolese et al, , 1994, we have routinely used this selected combination of reagents to establish more critically the diagnostic accuracy of the method in identifying otherwise undiagnosed SPTs. The results of this study, which reports our experience over the last 5 years, clearly demonstrate that this diagnostic approach offers an unprecedented accuracy in detecting SPTs, mainly in those lesions clearly malignant on the basis of cytological features, in which an undifferentiated morphology cannot permit establishment of their primary or metastatic nature.…”

Section: Discussionmentioning

confidence: 99%

“…aSee Mottolese et al (1988Mottolese et al ( , 1989Mottolese et al ( , 1990Mottolese et al ( , 1993Mottolese et al ( , 1994. b NS, not significant to detect tumour origin.…”

Section: Preparation Of Cell Substratesmentioning

confidence: 99%

“…The use of multiple MAbs, as we previously demonstrated on a large number of different cytological specimens, is imposed by the lack of absolute tumour specificity of the selected reagents and by the need to overcome the heterogeneous expression of TAAs, which may often result in false-negative findings. (Mottolese et al, 1988(Mottolese et al, , 1989(Mottolese et al, , 1993(Mottolese et al, , 1994.…”

Section: Preparation Of Cell Substratesmentioning

confidence: 99%

See 2 more Smart Citations

Identification of second malignancies on effusions and fine-needle aspirates using a panel of monoclonal antibodies

Mottolese¹,

Venturo

Rinaldi

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

Summary The longer survival of neoplastic patients achieved through improvements of therapeutic regimens has increased the relative risk of developing a second primary tumour (SPT). In this context, conventional cytopathology can define tumour histotype only in a small fraction of cases. In this study, we have evaluated whether selected combinations of monoclonal antibodies (MAbs) to tumour-associated antigens (TAAs) al, 1986;Tucker et al, 1988) and solid tumours (Lee, 1986;Kaldor et al, 1987). As early diagnosis of SPTs has major therapeutic and epidemiological relevance (Kaldor et al, 1987;Giardini et al, 1993), the development of new methods for the accurate detection of second malignancies should be attempted. In this context, exfoliative and FNA cytology may be considered a valuable and accurate diagnostic technique, easy to perform on a large scale during the follow-up of patients previously treated for malignant tumours. These methods also have the advantage of minimal morbidity and low cost (Koss, 1988). While this approach has been reported to be highly accurate in identifying metastatic cells, the possibility of defining the tumour histotype has been far less successful (Friedman et al, 1983;Hajdu et al, 1984). We have previously reported that the use of selected combinations of MAbs to TAAs can be applied to a number of areas of cytodiagnosis of solid tumours, thus increasing the accuracy of conventional morphology in identifying metastases from unknown primary tumour and in differentiating primary from metastatic lesions (Mottolese et al, 1993). In the present study, we have analysed, in a large group of patients with a past history of malignancy, whether the use of a similar panel of reagents may also be useful in detecting SPTs in two areas of cytopathology, which are particularly difficult on the basis of morphological criteria, namely that of effusions and of pulmonary FNA. MATERIALS AND METHODS PatientsFrom January 1990 to June 1995, 334 cytological specimens, of which 91 were pulmonary FNA and 243 pleural and peritoneal effusions sampled from patients previously treated with chemo and/or radiotherapy for different malignant tumours, were analysed both cytologically and immunocytochemically (ICC). The series consisted of 93 patients with effusions and 52 with solitary or multiple pulmonary masses, which appeared within 5 years of a previous tumour, while 189 patients developed effusions (150 cases) or radiologically assessed lung lesions (39 cases) at least 5 years after the first tumour. Only those cases in which morphological examination assessed the presence of malignant cells on cytological specimens have been included in this study. Unsatisfactory or insufficient specimens were excluded. Preparation of cell substratesPleural and peritoneal effusions were collected in sterile conditions using heparin (Liquemin Roche) as anticoagulant. Samples were centrifuged at 160 g for 10 min and the recovered cells were resuspended, after three washings with Hanks' balanced salt solution (Gibco Labor...

show abstract

Section: Discussionmentioning

confidence: 99%

“…aSee Mottolese et al (1988Mottolese et al ( , 1989Mottolese et al ( , 1990Mottolese et al ( , 1993Mottolese et al ( , 1994. b NS, not significant to detect tumour origin.…”

Section: Preparation Of Cell Substratesmentioning

confidence: 99%

Section: Preparation Of Cell Substratesmentioning

confidence: 99%

See 1 more Smart Citation

Identification of second malignancies on effusions and fine-needle aspirates using a panel of monoclonal antibodies

Mottolese¹,

Venturo

Rinaldi

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

show abstract

The use of a panel of monoclonal antibodies can lower false-negative diagnoses of peritoneal washings in ovarian tumors

Mottolese¹,

Salzano²,

Vincenzoni³

et al. 1991

Cancer

Self Cite

View full text Add to dashboard Cite

A correct surgical staging of ovarian carcinoma and the identification of persistent microscopic disease at second‐look surgery largely rely on the cytologic examination of peritoneal washings (PW). Nevertheless, the morphologic analysis of these fluids frequently provides false‐negative findings. As shown in other areas of cytodiagnosis, monoclonal antibodies (MoAb) to tumor‐associated antigens may be a useful adjunct to overcome the limitations of conventional cytopathologic examination of PW. To evaluate this question, immunocytochemical tests were done using a panel of four MoAb to ovarian carcinoma‐associated antigens (B72.3, MOv18, MOv19, and OC‐125) to analyze 117 PW sampled during initial surgical staging and 121 PW harvested at second‐look operations. The results of this study showed that immunocytochemical tests using the combination of the four reagents could improve cytodiagnosis more than 15% in both groups of PW. Thus a significant fraction of patients could be correctly staged and treated or become potentially curable by second‐line salvage therapy.

show abstract

Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens

Chhieng

Cangiarella

Zakowski

et al. 2001

Cancer

144

View full text Add to dashboard Cite

show abstract

Combinations of monoclonal antibodies can distinguish primary lung tumors from metastatic lung tumors sampled by fine needle aspiration biopsy

Cited by 8 publications

References 19 publications

Identification of second malignancies on effusions and fine-needle aspirates using a panel of monoclonal antibodies

Identification of second malignancies on effusions and fine-needle aspirates using a panel of monoclonal antibodies

The use of a panel of monoclonal antibodies can lower false-negative diagnoses of peritoneal washings in ovarian tumors

Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens

Contact Info

Product

Resources

About